Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
80 participants
INTERVENTIONAL
2010-10-31
2016-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Effect of Uric Acid Decrement on Endothelial Function in Patients With Chronic Renal Failure
NCT00978653
The Relationship Between Uric Acid and Inflammatory Markers
NCT01323335
Crossover Clinical Trial, Randomized, Double Blind, Placebo Controlled Trial
NCT04983160
Optimal Administration of Allopurinol in Dialysis Patients
NCT02477488
Center of Research Translation (CORT) Project 2
NCT02038179
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
1\) Allopurinol therapy and 2) Placebo.
Patients will receive: 3 month study drug (either allopurinol or placebo), with assessment of serum uric acid levels and vascular function.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Control
Patients who are randomized to this group will received placebo tablets. Placebo tables do not contain an active ingredient. This group will be used as a baseline group to compare the effects of lowering uric acid on vascular function.
Placebo
Placebo tablets with no active ingredient
Allopurinol
Patients who are randomized to this group will receive allopurinol tablets. Allopurinol is a medicine that lowers uric acid levels. The effects of lowering uric acid on vascular function outcomes will be assessed and compared to the control group.
Allopurinol
Xanthine oxidase inhibitor- effective at lowering uric acid levels.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Allopurinol
Xanthine oxidase inhibitor- effective at lowering uric acid levels.
Placebo
Placebo tablets with no active ingredient
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Elevated uric acid levels
* Age range: more than 18 years old
* Ability to give informed consent
* Albumin \> 3.0 g/dL
* BMI \< 40 kg/m2
Exclusion Criteria
* Expected to undergo living related kidney transplant in 6 months
* Pregnant, breast feeding, or unwilling to use adequate birth control
* History of severe liver disease
* History of severe congestive heart failure
* History of hospitalizations within 3 months
* Active infection, on antibiotics
* History of Warfarin Use or other medications that are contraindicated with allopurinol
* Uncontrolled hypertension
* History of acute gout on Allopurinol
* History of adverse reaction to Allopurinol
* Immunosuppressive therapy within the last 1 yr
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institutes of Health (NIH)
NIH
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
University of Colorado, Denver
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Diana Jalal, MD
Role: PRINCIPAL_INVESTIGATOR
University of Colorado, Denver
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Colorado at Denver
Aurora, Colorado, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Perrenoud L, Kruse NT, Andrews E, You Z, Chonchol M, Wu C, Ten Eyck P, Zepeda-Orozco D, Jalal D. Uric Acid Lowering and Biomarkers of Kidney Damage in CKD Stage 3: A Post Hoc Analysis of a Randomized Clinical Trial. Kidney Med. 2020 Feb 26;2(2):155-161. doi: 10.1016/j.xkme.2019.11.007. eCollection 2020 Mar-Apr.
Related Links
Access external resources that provide additional context or updates about the study.
What is the endothelium?
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
10-0625
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.